Taro’s Acquisition of Alchemee
February 22, 2022
On February 22, 2022, Taro Pharmaceutical Industries Ltd. (“Taro”), a multinational, science-based pharmaceutical company, and Galderma, the world’s largest independent dermatology company, announced they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company, from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv brand. Cravath is representing Taro in connection with the transaction.
The Cravath team includes associate Jason L. Zhang on M&A matters; partner Ronald E. Creamer Jr. on tax matters; partner Eric W. Hilfers and practice area attorney Arian Mossanenzadeh on executive compensation and benefits matters; partner David J. Kappos and associate Pedraam Mirzanian on intellectual property matters; partner Matthew Morreale on environmental matters; and of counsel Jesse M. Weiss and practice area attorney Nicole M. Peles on regulatory matters. Benjamin B. Arcano also worked on M&A matters.
Related Practices & Industries
People
- Photo
-
-
M.P.P.M., 1991, Yale University
-
J.D., 1991, Yale Law School
-
A.B., 1987, Princeton University
- New York
Education
Admitted In
- Photo
-
-
J.D., 1998, University of Chicago Law Schoolwith Honors
-
A.B., 1995, Princeton University
- New York
Education
Admitted In
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 1997, Columbia Law SchoolHarlan Fiske Stone Scholar
-
M.S., 1994, University of Pennsylvania
-
B.A., 1990, University of Pennsylvania
-
B.A.S., 1990, University of Pennsylvania
- New York
Education
Admitted In
- Photo
-
-
J.D., 2008, Georgetown University Law Centermagna cum laude
-
B.A., 2003, University of Maryland
- New York
Education
Admitted In
- Photo
-
-
J.D., 2010, New York University School of Lawcum laude
-
A.B., 2007, Dartmouth College
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
March 31, 2026
Biogen’s $5.6 Billion Acquisition of Apellis
On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.
Deals & Cases
March 09, 2026
Talkspace’s Acquisition by UHS
On March 9, 2026, Universal Health Services, Inc. (“UHS”) announced that it has entered into a definitive agreement to acquire Talkspace, Inc. (“Talkspace”) for $5.25 per share. The enterprise value for the transaction is approximately $835 million. Cravath is representing Talkspace in connection with the transaction.
Deals & Cases
February 18, 2026
Tenax’s Merger with Air
On February 17, 2026, Tenax Aerospace Acquisition, LLC (“Tenax”) and Air Industries Group (“Air”) jointly announced that they have entered into an Agreement and Plan of Merger to combine Tenax’s special mission aviation business with Air’s precision aerospace manufacturing business. At the time of the merger, Air will issue shares of its common stock to holders of Tenax membership units. After the closing, Tenax shareholders are expected to own approximately 95% of Air’s outstanding shares while existing Air shareholders are expected to own approximately 5%, and the combined company expects to remain listed on the NYSE American under the symbol AIRI. Cravath is representing Tenax in connection with the transaction.
Deals & Cases
February 17, 2026
Kennedy Wilson’s Acquisition by Consortium Led by William McMorrow and Fairfax
On February 17, 2026, Kennedy‑Wilson Holdings, Inc. (“Kennedy Wilson”) and Fairfax Financial Holdings Limited (“Fairfax”) jointly announced that Kennedy Wilson has entered into a definitive agreement to be acquired, in an all cash‑transaction, by an entity affiliated with a consortium led by William McMorrow, Chairman and Chief Executive Officer of Kennedy Wilson, and certain other senior executives of Kennedy Wilson (collectively, the “KW Management Group”), together with Fairfax (collectively, the “Consortium”).
